Published in Curr Opin Rheumatol on January 01, 2008
Mechanisms of immune complex-mediated neutrophil recruitment and tissue injury. Circulation (2009) 1.56
Neutrophil Extracellular Traps and Systemic Lupus Erythematosus. J Clin Cell Immunol (2013) 0.95
Translational mini-review series on immunology of vascular disease: mechanisms of vascular inflammation and remodelling in systemic vasculitis. Clin Exp Immunol (2009) 0.95
Anti-plasminogen antibodies compromise fibrinolysis and associate with renal histology in ANCA-associated vasculitis. J Am Soc Nephrol (2010) 0.95
The kidneys and ANCA-associated vasculitis: from pathogenesis to diagnosis. Clin Kidney J (2015) 0.88
Neutrophil extracellular trap components in fibrinoid necrosis of the kidney with myeloperoxidase-ANCA-associated vasculitis. Clin Kidney J (2013) 0.87
Neutrophils: game changers in glomerulonephritis? Trends Mol Med (2010) 0.86
Relation between asymptomatic proteinase 3 antibodies and future granulomatosis with polyangiitis. Clin J Am Soc Nephrol (2013) 0.82
Interventions for renal vasculitis in adults. A systematic review. BMC Nephrol (2010) 0.78
Autoantigenic nuclear proteins of a clinically atypical renal vasculitis. J Autoimmune Dis (2008) 0.76
Pathways to renal biopsy and diagnosis among patients with ANCA small-vessel vasculitis. Clin Exp Rheumatol (2013) 0.75
Clinicopathological characteristics and outcomes of Chinese patients with scanty immune deposits lupus nephritis: a large cohort study from a single center. ScientificWorldJournal (2014) 0.75
Vasculitides associated with IgG antineutrophil cytoplasmic autoantibodies in childhood. Pediatr Nephrol (2009) 0.75
Antineutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause glomerulonephritis and vasculitis in mice. J Clin Invest (2002) 5.42
Focal segmental glomerulosclerosis. N Engl J Med (2011) 3.77
Predictors of relapse and treatment resistance in antineutrophil cytoplasmic antibody-associated small-vessel vasculitis. Ann Intern Med (2005) 3.18
Autoimmunity is triggered by cPR-3(105-201), a protein complementary to human autoantigen proteinase-3. Nat Med (2003) 2.85
Alternative complement pathway in the pathogenesis of disease mediated by anti-neutrophil cytoplasmic autoantibodies. Am J Pathol (2007) 2.41
Predictors of treatment resistance and relapse in antineutrophil cytoplasmic antibody-associated small-vessel vasculitis: comparison of two independent cohorts. Arthritis Rheum (2008) 2.26
Venous thromboembolism in patients with membranous nephropathy. Clin J Am Soc Nephrol (2011) 2.18
Classification of antineutrophil cytoplasmic autoantibody vasculitides: the role of antineutrophil cytoplasmic autoantibody specificity for myeloperoxidase or proteinase 3 in disease recognition and prognosis. Arthritis Rheum (2012) 2.17
Pathogenesis of antineutrophil cytoplasmic autoantibody-associated small-vessel vasculitis. Annu Rev Pathol (2013) 2.02
Epitope specificity determines pathogenicity and detectability in ANCA-associated vasculitis. J Clin Invest (2013) 1.99
The role of neutrophils in the induction of glomerulonephritis by anti-myeloperoxidase antibodies. Am J Pathol (2005) 1.97
Association between thyroid disease and its treatment with ANCA small-vessel vasculitis: a case-control study. Nephrol Dial Transplant (2007) 1.89
Epigenetic basis for aberrant upregulation of autoantigen genes in humans with ANCA vasculitis. J Clin Invest (2010) 1.87
Anti-LAMP-2 antibodies are not prevalent in patients with antineutrophil cytoplasmic autoantibody glomerulonephritis. J Am Soc Nephrol (2011) 1.82
Periodontal disease adversely affects the survival of patients with end-stage renal disease. Kidney Int (2009) 1.74
Patients with antineutrophil cytoplasmic antibody-associated vasculitis have defective Treg cell function exacerbated by the presence of a suppression-resistant effector cell population. Arthritis Rheum (2013) 1.70
Aggravation of anti-myeloperoxidase antibody-induced glomerulonephritis by bacterial lipopolysaccharide: role of tumor necrosis factor-alpha. Am J Pathol (2005) 1.65
Rituximab therapy for membranous nephropathy: a systematic review. Clin J Am Soc Nephrol (2009) 1.62
SCreening for Occult REnal Disease (SCORED): a simple prediction model for chronic kidney disease. Arch Intern Med (2007) 1.56
The clinical course of ANCA small-vessel vasculitis on chronic dialysis. Kidney Int (2009) 1.54
Plasmapheresis therapy for diffuse alveolar hemorrhage in patients with small-vessel vasculitis. Am J Kidney Dis (2003) 1.53
DRB1*15 allele is a risk factor for PR3-ANCA disease in African Americans. J Am Soc Nephrol (2011) 1.51
Cutaneous and systemic manifestations of drug-induced vasculitis. Ann Pharmacother (2002) 1.48
Pathogenesis of vascular inflammation by anti-neutrophil cytoplasmic antibodies. J Am Soc Nephrol (2006) 1.48
Association of silica exposure with anti-neutrophil cytoplasmic autoantibody small-vessel vasculitis: a population-based, case-control study. Clin J Am Soc Nephrol (2007) 1.46
C5a receptor (CD88) blockade protects against MPO-ANCA GN. J Am Soc Nephrol (2013) 1.38
Granulomatosis with polyangiitis (Wegener's): an alternative name for Wegener's granulomatosis. Ann Rheum Dis (2011) 1.33
Periodontal disease is associated with renal insufficiency in the Atherosclerosis Risk In Communities (ARIC) study. Am J Kidney Dis (2005) 1.31
High prevalence of sickle cell trait in African Americans with ESRD. J Am Soc Nephrol (2010) 1.23
Bone marrow-derived cells are sufficient and necessary targets to mediate glomerulonephritis and vasculitis induced by anti-myeloperoxidase antibodies. J Am Soc Nephrol (2006) 1.20
Glucocorticoids and relapse and infection rates in anti-neutrophil cytoplasmic antibody disease. Clin J Am Soc Nephrol (2011) 1.20
Molecular cloning, genomic structure, and expression analysis of MUC20, a novel mucin protein, up-regulated in injured kidney. J Biol Chem (2003) 1.17
ANCA are pathogenic--oh yes they are! J Am Soc Nephrol (2002) 1.15
Circumvention of normal constraints on granule protein gene expression in peripheral blood neutrophils and monocytes of patients with antineutrophil cytoplasmic autoantibody-associated glomerulonephritis. J Am Soc Nephrol (2004) 1.14
Decreased CD5⁺ B cells in active ANCA vasculitis and relapse after rituximab. Clin J Am Soc Nephrol (2013) 1.12
Pathogenesis of antineutrophil cytoplasmic autoantibody vasculitis. Curr Opin Nephrol Hypertens (2011) 1.06
NPHS2 variation in focal and segmental glomerulosclerosis. BMC Nephrol (2008) 1.04
ANCA patients have T cells responsive to complementary PR-3 antigen. Kidney Int (2008) 1.02
A pilot study using mycophenolate mofetil in relapsing or resistant ANCA small vessel vasculitis. Nephrol Dial Transplant (2005) 1.02
Nosology of primary vasculitis. Curr Opin Rheumatol (2007) 1.01
Community perspectives on kidney disease and health promotion from at-risk populations in rural North Carolina, USA. Rural Remote Health (2010) 1.01
Anti-neutrophil cytoplasmic (ANCA) and anti-glomerular basement membrane (GBM) autoantibodies in necrotizing and crescentic glomerulonephritis. Semin Immunopathol (2007) 1.01
Fostering innovation, advancing patient safety: the kidney health initiative. Clin J Am Soc Nephrol (2013) 1.00
Successful treatment of diffuse alveolar hemorrhage with activated factor VII. Ann Intern Med (2004) 0.99
Expression profile of leukocyte genes activated by anti-neutrophil cytoplasmic autoantibodies (ANCA). Kidney Int (2002) 0.98
Granulomatosis with polyangiitis (Wegener's): an alternative name for Wegener's granulomatosis. J Am Soc Nephrol (2011) 0.98
Novel effects of neutrophil-derived proteinase 3 and elastase on the vascular endothelium involve in vivo cleavage of NF-kappaB and proapoptotic changes in JNK, ERK, and p38 MAPK signaling pathways. J Am Soc Nephrol (2002) 0.97
Predictors of treatment outcomes in ANCA-associated vasculitis with severe kidney failure. Clin J Am Soc Nephrol (2014) 0.96
Proteinase 3 sidesteps caspases and cleaves p21(Waf1/Cip1/Sdi1) to induce endothelial cell apoptosis. Kidney Int (2004) 0.95
Antibodies with dual reactivity to plasminogen and complementary PR3 in PR3-ANCA vasculitis. J Am Soc Nephrol (2008) 0.94
Obesity, albuminuria, and urinalysis findings in US young adults from the Add Health Wave III study. Clin J Am Soc Nephrol (2007) 0.93
Myeloperoxidase interacts with endothelial cell-surface cytokeratin 1 and modulates bradykinin production by the plasma Kallikrein-Kinin system. Am J Pathol (2007) 0.93
Rituximab in ANCA-associated disease. N Engl J Med (2010) 0.92
Various forms of life in antineutrophil cytoplasmic antibody-associated vasculitis. Ann Intern Med (2006) 0.92
Gene expression profiles of circulating leukocytes correlate with renal disease activity in IgA nephropathy. Kidney Int (2004) 0.91
Survival of liver transplant candidates with acute renal failure receiving renal replacement therapy. Kidney Int (2005) 0.91
Controversies in small vessel vasculitis--comparing the rheumatology and nephrology views. Curr Opin Rheumatol (2007) 0.90
Pharmacokinetics of mycophenolic acid in patients with lupus nephritis. Pharmacotherapy (2009) 0.89
Cyclophosphamide and 4-hydroxycyclophosphamide pharmacokinetics in patients with glomerulonephritis secondary to lupus and small vessel vasculitis. Br J Clin Pharmacol (2012) 0.89
Sera from patients with collapsing focal segmental glomerulosclerosis increase albumin permeability of isolated glomeruli. J Lab Clin Med (2004) 0.89
New insights that link microbes with the generation of antineutrophil cytoplasmic autoantibodies: the theory of autoantigen complementarity. Curr Opin Nephrol Hypertens (2005) 0.88
Severe periodontitis is associated with low serum albumin among patients on maintenance hemodialysis therapy. Clin J Am Soc Nephrol (2007) 0.88
Removing antibody and preserving glomeruli in ANCA small-vessel vasculitis. J Am Soc Nephrol (2007) 0.86
High basal activity of the PTPN22 gain-of-function variant blunts leukocyte responsiveness negatively affecting IL-10 production in ANCA vasculitis. PLoS One (2012) 0.86
B cell-mediated pathogenesis of ANCA-mediated vasculitis. Semin Immunopathol (2014) 0.85
Serum matrix metalloproteinases MMP-2 and MMP-3 levels in dialysis patients vary independently of CRP and IL-6 levels. Nephron (2002) 0.84
Influence of clinical and demographic variables on mycophenolic acid pharmacokinetics in antineutrophil cytoplasmic antibody-associated vasculitis. Ann Pharmacother (2009) 0.84
Genetically determined severity of anti-myeloperoxidase glomerulonephritis. Am J Pathol (2013) 0.83
Longitudinal studies of patients with ANCA vasculitis demonstrate concurrent reactivity to complementary PR3 protein segments cPR3m and cPR3C and with no reactivity to cPR3N. Autoimmunity (2010) 0.83
Monitoring proteinase 3 antineutrophil cytoplasmic antibodies for detection of relapses in small vessel vasculitis. Clin Diagn Lab Immunol (2003) 0.82
IL-17A in experimental glomerulonephritis: where does it come from? J Am Soc Nephrol (2010) 0.81
Reengineering clinical operations in a medical practice to optimize the management of anemia of chronic kidney disease. Pharmacotherapy (2007) 0.81
Primum non nocere: Should adults with idiopathic FSGS receive steroids? Semin Nephrol (2003) 0.81
CYP2C9 genotype and pharmacodynamic responses to losartan in patients with primary and secondary kidney diseases. Eur J Clin Pharmacol (2009) 0.81
Sickle trait in African-American hemodialysis patients and higher erythropoiesis-stimulating agent dose. J Am Soc Nephrol (2014) 0.80
Altered mRNA expression in renal biopsy tissue from patients with IgA nephropathy. Kidney Int (2003) 0.80
Use of enantiomeric bupropion and hydroxybupropion to assess CYP2B6 activity in glomerular kidney diseases. J Clin Pharmacol (2010) 0.80
Autoantigen complementarity: a new theory implicating complementary proteins as initiators of autoimmune disease. J Mol Med (Berl) (2004) 0.79
L1. Pathogenesis of ANCA-associated vasculitis: observations, theories and speculations. Presse Med (2013) 0.79
Antineutrophil cytoplasmic antibodies directed against bactericidal/permeability-increasing protein detected in children with cystic fibrosis inhibit neutrophil-mediated killing of Pseudomonas aeruginosa. Microbes Infect (2003) 0.79
Effects of uridine diphosphate glucuronosyltransferase 2B7 and 1A7 pharmacogenomics and patient clinical parameters on steady-state mycophenolic acid pharmacokinetics in glomerulonephritis. Eur J Clin Pharmacol (2010) 0.78
Variant hemoglobin phenotypes may account for differential erythropoiesis-stimulating agent dosing in African-American hemodialysis patients. Kidney Int (2011) 0.78
The rise and fall of horror autotoxicus and forbidden clones. Kidney Int (2010) 0.78
Alternative therapies and future intervention for treatment of membranous nephropathy. Semin Nephrol (2003) 0.78
In vivo alterations in drug metabolism and transport pathways in patients with chronic kidney diseases. Pharmacotherapy (2013) 0.78
Vasculitis: the elusive optimal induction strategy for vasculitis. Nat Rev Nephrol (2012) 0.78
Pathogenesis of pulmonary vasculitis. Semin Respir Crit Care Med (2004) 0.78
Human clinical trials in lupus nephritis. Semin Nephrol (2007) 0.78
Maintenance of tolerance by regulation of anti-myeloperoxidase B cells. J Am Soc Nephrol (2008) 0.77
A study of conformational restraints on reactivity of human PR3-specific autoantibodies (ANCA) facilitated through protein folding manipulations of a new recombinant proteinase 3 protein. Autoimmunity (2007) 0.76
Nursing Intervention Aimed at Improving Self-Managementfor Persons with Chronic Kidney Disease in North Carolina Medicaid: A Pilot Project. Nephrol Nurs J (2015) 0.76
Understanding the pathogenesis of ANCA: where are we today? Cleve Clin J Med (2002) 0.76
Vasculitis and anti-thyroid medication. Nephrol Dial Transplant (2007) 0.75
Autoantibodies: what's in their teeth? J Am Soc Nephrol (2011) 0.75
A pilot study of leukocyte expression patterns for drug metabolizing enzyme and transporter transcripts in autoimmune glomerulonephritis. Int J Clin Pharmacol Ther (2014) 0.75
Plasma exchange led to a higher rate of renal recovery than intravenous methylpredisolone in severe vasculitis. ACP J Club (2008) 0.75
L26. How antigens influence the disease: an immunologist point of view. Presse Med (2013) 0.75
The Evolving Role of Rituximab in Adult Minimal Change Glomerulopathy. Am J Nephrol (2017) 0.75
The Kidney Care Prevention Program: an innovative approach to chronic kidney disease prevention. N C Med J (2008) 0.75
Clinical Features and Outcomes of a Racially Diverse Population with Fibrillary Glomerulonephritis. Am J Nephrol (2017) 0.75